Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6221392	UCB INC	Rapidly dissolving robust dosage form	Apr, 2018 (6 years ago)
US6024981	UCB INC	Rapidly dissolving robust dosage form	Apr, 2018 (6 years ago)

Niravam is owned by Ucb Inc.

Niravam contains Alprazolam.

Niravam has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Niravam are:

Niravam was authorised for market use on 19 January, 2005.

Niravam is available in tablet, orally disintegrating;oral dosage forms.

The generics of Niravam are possible to be released after 09 April, 2018.

Market Authorisation Date: 19 January, 2005

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
0.25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
0.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

Niravam patents expiration